Literature DB >> 6694738

Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization.

J O Dolly, J Black, R S Williams, J Melling.   

Abstract

Botulinum neurotoxin (BoNY) type A, a causative agent of botulism, is a di-chain protein (molecular weight 140,000) from Clostridium botulinum, and the most neurotoxic substance known. Some cases of sudden infant cot deaths have been attributed to such a neuroparalytic condition. BoNT inhibits irreversibly the release of acetylcholine from peripheral nerves in a highly selective manner. Hence, it is potentially an invaluable probe for studying the mechanism of transmitter release. Here we demonstrate specific labelling of murine motor nerve terminals with neurotoxic, 125I-labelled BoNT (type A) by autoradiography. We observed saturable, temperature-sensitive binding of BoNT to sites which reside solely on the nerve terminal membrane; these were distributed on all unmyelinated areas, at an average density of 150-500 per micron2 of membrane. The binding was mediated by the larger subunit of the toxin and was inhibited partially by tetanus toxin, another microbial protein. No specific binding was detectable on any other cell types examined, including noradrenergic terminals. Following binding, internalization of radioactivity was observed; this process was energy-dependent as it could be prevented totally by azide or dinitrophenol (DNP). This direct demonstration of separable steps, including highly selective binding and acceptor-mediated internalization, is reconcilable with the unique potency and the multiphasic inhibitory action of BoNT on transmitter release, as shown electrophysiologically.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6694738     DOI: 10.1038/307457a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  56 in total

Review 1.  Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use.

Authors:  P Hambleton
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

2.  Structural analysis of botulinum neurotoxin types A and E in aqueous and nonpolar solvents by Fourier transform infrared, second derivative UV absorption, and circular dichroic spectroscopies.

Authors:  B R Singh; F M Wasacz; S Strand; R J Jakobsen; B R DasGupta
Journal:  J Protein Chem       Date:  1990-12

3.  Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism.

Authors:  Callista B Harper; Sally Martin; Tam H Nguyen; Shari J Daniels; Nickolas A Lavidis; Michel R Popoff; Gordana Hadzic; Anna Mariana; Ngoc Chau; Adam McCluskey; Phillip J Robinson; Frederic A Meunier
Journal:  J Biol Chem       Date:  2011-08-05       Impact factor: 5.157

4.  Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes.

Authors:  Clifford Shone; Heidi Agostini; Joanna Clancy; Mili Gu; Huei-Hsiung Yang; Yanfang Chu; Virginia Johnson; Makie Taal; Joanna McGlashan; John Brehm; Xiaomi Tong
Journal:  Infect Immun       Date:  2009-04-27       Impact factor: 3.441

5.  The effects of nerve terminal activity on non-quantal release of acetylcholine at the mouse neuromuscular junction.

Authors:  H Zemková; F Vyskocil; C Edwards
Journal:  J Physiol       Date:  1990-04       Impact factor: 5.182

6.  Evaluating the role of botulinum toxin in the management of focal hypertonia in adults.

Authors:  D Richardson; G Sheean; D Werring; M Desai; S Edwards; R Greenwood; A Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-10       Impact factor: 10.154

7.  Conversion of mechanical force into TGF-β-mediated biochemical signals.

Authors:  Toru Maeda; Tomoya Sakabe; Ataru Sunaga; Keiko Sakai; Alexander L Rivera; Douglas R Keene; Takako Sasaki; Edward Stavnezer; Joseph Iannotti; Ronen Schweitzer; Dusko Ilic; Harihara Baskaran; Takao Sakai
Journal:  Curr Biol       Date:  2011-05-19       Impact factor: 10.834

Review 8.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

9.  Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons.

Authors:  Min Dong; Huisheng Liu; William H Tepp; Eric A Johnson; Roger Janz; Edwin R Chapman
Journal:  Mol Biol Cell       Date:  2008-09-24       Impact factor: 4.138

10.  Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.

Authors:  A Nowakowski; C Wang; D B Powers; P Amersdorfer; T J Smith; V A Montgomery; R Sheridan; R Blake; L A Smith; J D Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.